On February 10, Veolizhibo (09887) announced that the company is pleased to announce that Veolizhibo (PD-L1/4-1BB bispecific antibody opatidisulfimab, LBL-024) has been successfully administered to the first patient in the Phase IB/II trial of recurrent or metastatic triple-negative breast cancer.
This trial, led by Professor Yin Yongmei of Jiangsu Provincial People's Hospital, aims to evaluate the efficacy and safety of opatitumumab alone or in combination with albumin-bound paclitaxel.
Verlisin is a bispecific antibody that simultaneously targets PD-L1 and 4-1BB, possessing broad-spectrum cancer treatment potential. In two clinical trials in China, this drug demonstrated promising efficacy and safety in patients with advanced extrapulmonary neuroendocrine carcinoma, whether used as monotherapy or in combination with chemotherapy.
In addition, the company received approval from the National Medical Products Administration to conduct a single-arm registration clinical trial in April 2024, obtained Breakthrough Therapy Designation for the treatment of late-line advanced extrapulmonary neuroendocrine carcinoma in October 2024, and obtained Fast Track and Orphan Drug Designations from the FDA and the European Commission in January 2026.
https://finance.eastmoney.com/a/202602103646715549.html